Press "Enter" to skip to content

Pharmaceutical Giant Pfizer Ramping Up Production Amid J&J vaccine pause

Pharmaceutical Giant Pfizer said on Thursday that it is preparing to ramp up production of its Covid-19. It comes a day after the US Federal Administration amended a pause on administering injections of the Johnson & Johnson vaccine over health concerns. In a Twitter post, Pfizer CEO confirmed the news.

Pfizer CEO Albert Bourla said that the company could exceed its production by 10% than previously agreed to. Now the limit of the vaccine doses will increase to 220 million, and it is projected to be administered by the end of May. He said that Pfizer will be able to supply its full quota of 300 million doses to the US health departments by the end of July. The timeline is two weeks ahead of what the pharmaceutical giant’s officials predicted.

The extra doses of the Pfizer vaccine may help to compensate for the shortage in doses caused by the suspension of the Johnson & Johnson vaccine. Whether or not the health officials upheld the temporary closure is uncertain due to large-scale health risks.Federal health agencies on Tuesday suggested a pause on administering the Johnson & Johnson vaccine after reports of blood clots surged across the states. While the agencies dig deeper into the reports from several women between the age of 18 and 48 who said they fell ill with a rare and severe type of blood clot. As per the detailed examination, these came out two weeks later after the women inoculated the vaccine, and resulted in an unfortunate demise of a woman.

“We believe there’s enough vaccine in the system — Moderna and Pfizer — for all Americans who want to get vaccinated by May 31 to do so,” said Jeff Zients, the White House’s COVID-19 response coordinator. This came after Jonhson & Johnson said that the health and the safety of people who use their vaccine is its number one priority.

Be First to Comment

Leave a Reply

Your email address will not be published.